ELEV vs. CMPX, PSTX, XFOR, IPSC, OPT, ADVM, IPHA, ABOS, STRO, and CRDF
Should you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Compass Therapeutics (CMPX), Poseida Therapeutics (PSTX), X4 Pharmaceuticals (XFOR), Century Therapeutics (IPSC), Opthea (OPT), Adverum Biotechnologies (ADVM), Innate Pharma (IPHA), Acumen Pharmaceuticals (ABOS), Sutro Biopharma (STRO), and Cardiff Oncology (CRDF). These companies are all part of the "biological products, except diagnostic" industry.
Elevation Oncology (NASDAQ:ELEV) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.
83.7% of Elevation Oncology shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 14.9% of Elevation Oncology shares are owned by insiders. Comparatively, 30.0% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Elevation Oncology had 1 more articles in the media than Compass Therapeutics. MarketBeat recorded 2 mentions for Elevation Oncology and 1 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 0.25 beat Elevation Oncology's score of 0.02 indicating that Compass Therapeutics is being referred to more favorably in the news media.
Elevation Oncology currently has a consensus target price of $7.25, suggesting a potential upside of 100.28%. Compass Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 520.69%. Given Compass Therapeutics' higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Elevation Oncology.
Compass Therapeutics' return on equity of -26.07% beat Elevation Oncology's return on equity.
Elevation Oncology has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.
Compass Therapeutics is trading at a lower price-to-earnings ratio than Elevation Oncology, indicating that it is currently the more affordable of the two stocks.
Compass Therapeutics received 1 more outperform votes than Elevation Oncology when rated by MarketBeat users. Likewise, 71.88% of users gave Compass Therapeutics an outperform vote while only 66.67% of users gave Elevation Oncology an outperform vote.
Summary
Compass Therapeutics beats Elevation Oncology on 9 of the 14 factors compared between the two stocks.
Get Elevation Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELEV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevation Oncology Competitors List
Related Companies and Tools
